[The Fair = Reporter Ho-Jun Son] Over 50 pharmaceutical and medical device companies participated in the Korean Orthopedic Association Autumn Symposium, showcasing their innovations. Among the exhibits, REV-MED’s products used in the newly recognized Autologous Bone Marrow Stem Cell Injection Therapy received significant attention.
Revolutionary Autologous Stem Cell Therapy
REV-MED’s device complies with the Ministry of Health and Welfare’s Directive No. 2023-128 (July 11, 2023), which recognizes the treatment involving centrifugation and concentration of autologous bone marrow stem cells for intra-articular injection into the knee joint cavity. This treatment, developed entirely with Korean technology, is the third of its kind worldwide.
The kit features:
- Bone Marrow Filter: Removes impurities during bone marrow extraction.
- Dual Centrifugation Process:
- First centrifugation eliminates red blood cells.
- Second centrifugation concentrates functional cells, including stem cells.
- Three-Chamber Design: Enhances functionality and scalability for global markets.
REV-MED holds five patents and an additional 10 related patents and designs for this innovative technology, positioning it as a leader in both domestic and international markets.
Focus on Stem Cell Research
REV-MED is heavily invested in its stem cell research center. A company representative stated, “Key data on stem cell markers, proliferation ability, differentiation potential, and gene expression in differentiated cells were published in the Annals of Translational Medicine in 2020, before the technology received official recognition.”
The company emphasized its commitment to advancing the field of skeletal stem cell therapy through ongoing research and innovation.
Source: The Fair (https://www.thefairnews.co.kr)
[The Fair = Reporter Ho-Jun Son] Over 50 pharmaceutical and medical device companies participated in the Korean Orthopedic Association Autumn Symposium, showcasing their innovations. Among the exhibits, REV-MED’s products used in the newly recognized Autologous Bone Marrow Stem Cell Injection Therapy received significant attention.
Revolutionary Autologous Stem Cell Therapy
REV-MED’s device complies with the Ministry of Health and Welfare’s Directive No. 2023-128 (July 11, 2023), which recognizes the treatment involving centrifugation and concentration of autologous bone marrow stem cells for intra-articular injection into the knee joint cavity. This treatment, developed entirely with Korean technology, is the third of its kind worldwide.
The kit features:
REV-MED holds five patents and an additional 10 related patents and designs for this innovative technology, positioning it as a leader in both domestic and international markets.
Focus on Stem Cell Research
REV-MED is heavily invested in its stem cell research center. A company representative stated, “Key data on stem cell markers, proliferation ability, differentiation potential, and gene expression in differentiated cells were published in the Annals of Translational Medicine in 2020, before the technology received official recognition.”
The company emphasized its commitment to advancing the field of skeletal stem cell therapy through ongoing research and innovation.
Source: The Fair (https://www.thefairnews.co.kr)